No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SGHT240621P5000
- 0.09
- -0.16-64.00%
15min DelayClose Jun 14 16:00 ET
0.09High0.09Low
0.09Open0.25Pre Close10 Volume750 Open Interest5.00Strike Price90.00Turnover196.10%IV25.15%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.1063Delta0.1156Gamma72.89Leverage Ratio-0.0257Theta-0.0001Rho-7.75Eff Leverage0.0015Vega
Intraday
- 5D
- 1D
News
Sight Sciences Announces the Release of Its First Sustainability Report
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We can see that Sight Sciences, Inc. (NASDAQ:SGHT) does use debt in its business. But the real question is whether this debt is making the company risky.
Predictive Oncology, Augmedix, Cue Health Among Healthcare Movers
Express News | Sight Sciences Announces Publication Of Twelve-Month Results Of SAHARA RCT Data Demonstrating Improved Signs And Symptoms Of Dry Eye Disease For TearCare Patients Crossed Over FFom Restasis
Express News | Sight Sciences Announces the Publication of Twelve-Month Results of the Sahara Rct Demonstrating Improved Signs and Symptoms of Dry Eye Disease for Tearcare Patients Crossed Over From Restasis
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating...
Comments
$Sight Sciences(SGHT.US$
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...
1
$Sight Sciences(SGHT.US$
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...
Revolutionizing Glaucoma and Dry Eye Treatment: Insights from Sight Sciences' Groundbreaking Clinical Trials.
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...
Sight Sciences' high P/S ratio may be precarious given forecasted revenue declines, posing the risk of a future drop in share prices despite recent gains.
$Sight Sciences(SGHT.US$ crazy day, what is going on?!
Read more